Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RALAM-II Study: Simplification Study With Dual Therapy Including Lamivudine Plus Raltegravir in Virologically Suppressed HIV-1 Infected Patients
NCT03333083Phase 3Terminated
- Start
- May 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of raltegravir and lamivudine in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoint: Therapeutic failure at 48 weeks. Started May 2018; status: terminated.
02
Drugs
raltegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03333083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333083.